Skip to content
WorldBrand.AI

Shineway Pharmaceutical

Controversies

Controversies tied to this brand in public sources. A listing is not a finding of fault.

Back to profile1 entries

  1. 2022

    Lianbizhi Injection registration revoked over kidney injury risk; formula granules fail spot check

    Lianbizhi Injection had previously been warned that it might cause acute kidney injury; in 2022 the National Medical Products Administration decided, based on post-marketing evaluation, to stop its production, sale and use and to cancel its drug registration certificate, with Shineway Pharmaceutical among the companies involved. In 2023 a batch of Shineway's fried sour jujube seed formula granules failed the microbial limit and was announced. Production and use of Lianbizhi were stopped; the non-compliant batch was ordered to be suspended from sale and recalled.

    Source